Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors78

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors18

Views

Views
November 20256
December 20252
January 20261
February 20260
March 20264
April 20264
May 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Brazil2
France2
Argentina2
United Kingdom1
Kenya1
Morocco1
Mexico1
Romania1
 

Top cities views

Views
Rosario2
Ashburn1
Atlanta1
Bauru1
Des Moines1
Fes1
Porto Alegre1
San Jose1
Xalapa1